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Objective: Leigh syndrome is a neurodegenerative disorder with 
an incidence of 1:40,000 live births. It presents wide clinical, 
biochemical, and genetic heterogeneity, but with homogenous 
neuropatoradiological alterations. There is no specific treatment, 
and the prognosis is reserved. This case report aimed familiarize 
health professionals with the disease.
Case Description: A 16-month-hold girl who was followed 
in outpatient clinic due to axial hypotonia and delayed 
psychomotor development. Karyotype, auditory evoked 
potentials and ophthalmologic evaluation were normal. Evidence 
of hyperlactacidemia and hypocitrullinemia was detected in 
the patient. After performing brain magnetic resonance under 
anesthesia, hypotonia got worse, and the patient was hospitalized 
after an episode of cyanosis and apnea. The electroencephalogram 
showed no epileptiform activity. Neuroimaging revealed bilateral 
lenticular hyperintensity, especially in the putamen and in the left 
globus pallidus regions. Molecular analysis revealed an 8993T>G 
(MT-ATP6) mutation in the mitochondrial DNA.
Comments: Between 10 and 30% of individuals with Leigh 
syndrome have mitochondrial DNA mutations. The decompensation 
after anesthetic intercurrences is typically associated with 
neurological deterioration and, in this case, increased the diagnosis 
suspicion. It is important to alert for similar cases and to reduce 
invasive diagnostic tests if the diagnosis is suspected.
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Objetivo: A síndrome de Leigh é uma doença neurodegenerativa 
com incidência de 1:40.000 nados-vivos. Apresenta ampla 
heterogeneidade clínica, bioquímica e genética, mas com alterações 
neuropatorradiológicas homogêneas. Não existe tratamento 
específico, e o prognóstico é reservado. O objetivo deste estudo 
foi familiarizar os profissionais de saúde com a doença.
Descrição do caso: Menina de 16 meses, com hipotonia axial e 
atraso do desenvolvimento psicomotor. Dos exames realizados: 
cariótipo, potenciais auditivos evocados e avaliação oftalmológica 
normais; presença de hiperlactacidemia e hipocitrulinemia. Após a 
realização de ressonância magnética cerebral sob anestesia, 
observou-se agravamento da hipotonia com necessidade de 
internação por episódios de cianose/apneia. O eletroencefalograma 
não mostrou atividade epileptiforme. A neuroimagem revelou 
hipersinal lenticular bilateral com lesão do putâmen e do globo 
pálido esquerdo. Encontrou-se a mutação 8993T>G (MT-ATP6) 
no DNA mitocondrial.
Comentários: De 10 a 30% dos doentes com síndrome de Leigh 
apresentam mutações do DNA mitocondrial. A descompensação 
com agravamento neurológico após intervenção anestésica está 
descrita e, nesse caso, apoiou o diagnóstico. Importante alertar 
para casos semelhantes, com diminuição de exames invasivos 
para diagnóstico.
Palavras-chave: ATPase6; Citopatia mitocondrial; Síndrome de 
Leigh; Lactente.
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INTRODUCTION
Leigh syndrome (LS) is a hereditary neurometabolic disease, 
also known as subacute necrotizing encephalomyelopathy, and 
was described by the British neuropathologist and psychia-
trist Denis Leigh in 1951. It is a neurodegenerative disease 
with variable symptoms that occurs due to a mitochondrial 
dysfunction caused by a hereditary genetic defect, associated 
with bilateral central nervous system lesions. Although it is a 
rare disease, with an approximate incidence of 1:40,000 live 
births, it is the most frequent mitochondrial disease in the 
first year of life.1-7
The heterogeneous functional nature of the mitochon-
dria is responsible for the broad spectrum of clinical man-
ifestations that characterize LS. A dysfunction is present 
in a restricted but vital area of mitochondrial metabolism, 
oxidative phosphorylation, in which most cellular adenos-
ine triphosphate (ATP) is produced. Thus, any organ can 
be affected, but tissues with higher oxygen needs, such as 
the skeletal muscle, the heart and the nervous system, are 
usually the most affected.8,9 
The association of neurological symptoms and signs, which 
can not be explained in terms of the anatomical topography 
of lesions or because they preferentially reach specific systems, 
may evoke this diagnosis, and there are no specific clinical 
signs of mitochondrial cytopathy.8,9 Although most of the 
symptomatology is neurologic, some patients may present 
non-neurological manifestations or even multisystem involve-
ment.2,4,10 Neurological manifestations may include delayed 
psychomotor development, muscle weakness, hypotonia, dys-
tonia, spasticity, epilepsy, ataxia, intentional tremor, nystag-
mus, ophthalmoparasia, optic atrophy, dysphagia, respiratory 
impairment, deafness, paralysis of peripheral cranial nerves, 
polyneuropathy and myopathy. The most frequent non-neu-
rological manifestations include dysmorphic and endocrine 
(short stature, hypertrichosis, diabetes), cardiac (dilated or 
hypertrophic cardiomyopathy) or gastrointestinal abnormal-
ities (diarrhea, vomiting).2,4,10 
In LS, aside from the wide clinical heterogeneity, there are 
also genetic and biochemical variabilities, which contrast with 
the neuropatoradiological homogeneity.1-5 The genetic etiol-
ogy is confirmed in about 50% of cases, with more than 60 
mutations identified in nuclear or mitochondrial DNA, the 
latter being responsible for about 10 to 30% of the cases.1-3,6,7,11 
One of the most frequently mutated mitochondrial genes is 
the ATPase6 (MT ATP6) gene, which encodes a subunit of 
complex V of the respiratory chain, with the most frequently 
described mutation being the 8993T>G transversion.2,4,5,9,12 
Although hypocitrulinaemia (≤12 μmol/L) is an occasional 
finding in mitochondrial diseases, it has been specifically 
associated with the 8993T>G mutation; however, its prev-
alence is unknown.6,12 Other biochemical markers that are 
suggestive of LS are high plasma lactate levels (by glucose 
overload) and increased lactate/pyruvate ratio; however, their 
absence does not exclude the diagnosis.1,6
Faced with clinical and laboratorial suspicion of LS, cranio-
encephalic magnetic resonance imaging (MRI) should be per-
formed. The most common findings in T2-weighted imaging 
are focal, bilateral, and symmetric hyperintensities typically 
located in the basal ganglia (especially the putamen) and/or 
in the brainstem. Other frequently involved areas are the thal-
amus, substantia nigra, red nucleus, brainstem, cerebellum, 
cerebral white matter, or spinal cord.2,6,7,13 These lesions, evi-
dent both in the brain imaging and i then anatomopatholog-
ical studies, are attributed to ATP depletion, with consequent 
lactoacidosis, vascular congestion, hypoxia and, finally, necro-
sis. The preferential involvement of the subcortical regions is 
attributed to the greater vulnerability to lactoacidose, which 
seems to be secondary to its vascular support, the penetrat-
ing arterioles.2,4,14
The prognosis of LS is reserved and there is no specific treat-
ment, and multidisciplinary palliative care should be performed.1
CASE REPORT
Female infant, referred to pediatric consultation at eight 
months of age due to axial hypotonia and Global Psychomotor 
Development Retardation (PDR). She did not present any 
relevant perinatal (somatometry at birth was appropriate to 
gestational age), personal or family antecedents (no history 
of consanguinity). The objective examination confirmed 
hypotonia, but showed no other peculiarities, namely, no 
dysmorphia. An analytical investigation was carried out, 
which revealed no alterations, namely: CBC, glucose, cre-
atinine, urea, sodium, potassium, chlorine, calcium, phos-
phorus, creatine kinase (CK), lactate dehydrogenase (LDH), 
transaminase, alkaline phosphatase (ALP), lipid profile, thy-
roid function, and venous blood gases. Type II urine/uri-
nary sediment, transfontanelar echography, and karyotype 
(46, XX in peripheral blood) tests were also performed, 
which were also normal.
At nine months of age, the patient started physiotherapy 
thrice a week, having completed six months of treatment. 
Only mildly improved hypotonia was observed, with mainte-
nance of PDR, which is why CE-MRI was chosen.
At 16 months of age, one day after performing the CE-MRI 
with anesthesia, the child was admitted to the emergency ser-
vice (ES) due to a hyporativity episode. There was a paren-
tal notion of greater prostration in the hours preceding that 
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episode. Objectively, on admission, there was little reactivity, 
aggravated axial hypotonia, increased osteotendinous reflexes, 
and cutaneous pallor. The analytical investigation (which was 
still within normality) was repeated, a urine drug screening 
(negative) was performed, and the patient’s hospitalization 
surveillance was chosen.
On the first day of hospitalization, there was an episode 
of generalized cyanosis and apnea, with spontaneous recovery 
followed by somnolence and prostration. An electroencepha-
logram was performed, which showed a globally altered tra-
jectory, with low amplitude and poor definition of the phys-
iological elements. Treatment with phenytoin was started at 
10 mg/kg/day, with no recurrence of the episodes; however, 
severe axial hypotonia and prostration were maintained, with 
poor social interaction.
In the T2-weighted CE-MRI images, bilateral and len-
ticular hypersignal was observed, expressed in the putamen, 
and there was doubt regarding the left pallid globe, which 
suggested the diagnosis of metabolic disease, especially in the 
absence of intercurrences during gestation and peripartum 
(Figures 1 e 2). From the metabolic investigation performed, 
hypocitrulinaemia at 5 μmol/L (normal levels are 15 to 
30 μmol/L) and hyperlactacidemia at 3.0 mmol/L (normal 
levels are 0.5 to 2.2 mmol/L). The patient presented normal 
serum pyruvate, ammonia, and organic acid chromatography. 
Evoked potentials of the brainstem, electrocardiogram, and 
echocardiogram were also performed, which did not show 
any alterations. She was evaluated by an ophthalmologist, 
and the examination was within normality.
Considering the clinical, laboratory, and imaging data and 
the suspicion of LS, a panel of mitochondrial genes was car-
ried out, with the identification of the 8993T>G mitochon-
drial DNA mutation (MT ATP6; heteroplasmy greater than 
90%), thus confirming the diagnostic hypothesis. She was 
referred to consultation at the Reference Center for Hereditary 
Metabolism Diseases, and was given vitamin supplementation 
with thiamine, riboflavin, and coenzyme Q10. Parents were 
informed about the risk of sedation or anesthesia. The mater-
nal family investigation was positive for the same mutation, 
with 75% heteroplasmy.
During follow-up, the child developed ataxia, dystonia, 
and epilepsy with a myoclonic component. There was thera-
peutic substitution for phenobarbital and levetiracetam, with 
good response. She underwent physical therapy and began 
occupational therapy.
Figure 1 Axial cut of the cranioencephalic magnetic 
resonance (T2) of the patient with Leigh syndrome 
and 8993T>G mutation. The arrows show the bilateral 
lenticular hypersignal.
Figure 2 Coronal cut of the cranioencephalic magnetic 
resonance (T2 weighting) of the patient with Leigh 
syndrome and 8993T>G mutation. The arrows show 
the bilateral lenticular hypersignal.
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DISCUSSION
Although LS is a mitochondrial disease, it is not characterized by 
the specific clinical signs of this group of diseases, which makes 
its diagnosis a medical challenge. The wide clinical, laborato-
rial, and genetic variability should be known, in order to enable 
earlier diagnosis and, thus, to improve the quality of life.1-6,8-11
This is the report of an LS case with onset of symptoms under 
two years of age, that is, the most frequent variant of the disease: 
the infant form.1,3,5,6,10,11 Usually, LS manifests itself with a progres-
sive decline of central nervous system function.2,10 In the case pre-
sented, the initial symptoms were PDR and axial hypotonia, and 
the subacute presentation of the disease was considered.1,3,5,6,10,11 
During the first months of follow-up of the patient and once 
she presented a normal analytical and karyotype investigation, 
as well as normal transfontanelar ultrasound, an expectant fol-
low-up with physiotherapy was chosen. However, as there was 
no significant improvement, the study of central hypotonia was 
started with the application of CE-MRI.
The initial diagnostic suspicion of LS appeared one day after 
the CE-MRI, in which the patient was submitted to anesthesia 
with consequent neurological aggravation. In this case, this aggra-
vation arose from metabolic stress induced by the anesthetic pro-
cedure, but it may be induced by infections, vaccination, or peri-
ods of fasting, which is usual in patients with this entity.1,3,5,6,10,11
The neuroimaging alterations found, along with hyperlac-
tacidemia and hypocitrulinaemia, reinforced the diagnostic 
hypothesis. For this reason, the genetic investigation focused 
on the mitochondrial panel of genes, with the 8993T>G muta-
tion. Although more studies are needed, this mutation should 
be considered early in the diagnostic evaluation of childhood 
mitochondrial diseases with hypocitrulinaemia, which mini-
mizes the need for invasive procedures, such as muscle biop-
sies, associated with a small but not negligible risk of complica-
tions.6,12 It is known that the supply of citrulline through diet 
is minimal, and enterocytes are the main site of its synthesis 
(via proline ornithine citrulline, which requires the carbamyl-
phosphate I-ATP-dependent reaction). Thus, in LS, hypoci-
trinemia is thought to be related to altered intestinal biosynthe-
sis of citrulline, secondary to the lack of ATP in enterocytes.12
At the time of diagnosis, the ophthalmologic involve-
ment of the cardiac muscle (normal electrocardiogram and 
echocardiogram), musculoskeletal involvement (normal CK) 
and brainstem involvement (normal evoked auditory potentials) 
were excluded. During the follow-up, the development of ataxia, 
dystonia, and epilepsy were observed, which are described in 
LS patients.2,10 However, the screening of other manifestations 
with which LS can occur, neurological or otherwise, remains 
important during the course of follow-up, as these manifesta-
tions may appear later in evolution.2,4,10
Neuropathy, ataxia and retinitis pigmentosa syndrome (NARP), 
also associated with the 8993T>G mutation in the MT-ATP6 mito-
chondrial gene, usually occurs in young adults, as a combination 
of salt-and-pepper retinopathy, muscle weakness, ataxia, and sen-
sory neuropathy. This mutation occurs in 8 to 10% of LS cases, 
representing a more severe phenotypic presentation of NARP.15
Although there is no curative therapy for LS, multidisci-
plinary palliative care is essential. The use of some substances 
has been proposed for the treatment of LS, such as coenzyme 
Q10, carnitine, lipoic acid, biotin, riboflavin and others; how-
ever, there is no clear evidence of their effectiveness.1,6,14 In the 
case presented, supplementation with thiamine, riboflavin, and 
coenzyme Q10 was performed, without impediment of the 
progressive aggravation that is characteristic of LS.1 The aver-
age survival of patients with LS in childhood is five years, and 
the current age of the patient described here is three years.2
Prenatal diagnosis (PND) is rarely performed in mitochon-
drial cytopathies with mitochondrial DNA mutation, due to the 
low reliability of the procedure, since the percentage of hetero-
plasm varies throughout gestation.2,6 However, exceptionally, the 
PND for this mutation may be made available due to the high 
percentage presented in all organs in the affected cases.16 In this 
way, and considering that the mother has the same mutation, 
the genetic counseling of this family is of extreme importance.
In conclusion, the authors want to alert to the importance 
of early recognition of LS, allowing maximization of the qual-
ity of life of these patients and their families.
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